BioSpace News Archive

This patent includes RXI-109 and its use in dermal scarring, for which the safety and efficacy was shown in a recent Phase 2 clinical trial with statistically significant outcomes for improved visual appearance for RXI-109 treated scar over control.

Alcami continues to set the industry standard with its analytical testing offering, and through operational excellence, streamlined processes, and technical knowledge and expertise, has reduced timelines by up to 30 percent.

Aetion Evidence Platform aims to replicate 30 published randomized clinical trials with real-world data analyses

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2018. In addition, the Company provided a clinical and business update. As of March 31, 2018, Syndax had $113.2 million in cash, cash equivalents and short-term investments.